How Does UnitedHealth Group Make Money?

UnitedHealth Group (UNH) faces scrutiny amid a significant stock decline, driven by rising medical costs and a criminal investigation into its Medicare & Retirement segment, which generated $139.5B in revenue and $8.4B in EBITDA in 2024. While UnitedHealthcare contributes 54% to total revenue, Optum, with segments like Optum Health and Optum Rx, is increasingly vital, accounting for 46% of revenue and higher EBITDA margins; however, Optum Rx faces potential disruption from regulatory changes targeting pharmacy benefit managers. The outcome of both the criminal investigation and potential PBM reforms pose significant challenges to UnitedHealth's future trajectory.

Analysis

UnitedHealth Group (UNH) is navigating a period of intense scrutiny, evidenced by a stock decline exceeding 50% since April, a strongly negative sentiment score of -0.75, and a high market impact score of 0.85. The company's revenue is generated through two primary businesses: UnitedHealthcare, contributing 54% of total 2024 revenues, and Optum, accounting for the remaining 46%. Optum's share of revenue has notably increased from 41% in 2021, indicating a strategic shift, while UnitedHealthcare's share has decreased from 59%. Within UnitedHealthcare, the Medicare & Retirement segment, which generated $139.5 billion in revenue (25% of total) and $8.4 billion in EBITDA (23% of total) in 2024, is currently under a criminal investigation for possible fraud, posing a significant risk. The broader UnitedHealthcare business is also experiencing pressure on profit margins due to rising medical costs. Optum, focused on healthcare modernization, comprises Optum Health, Optum Insight, and Optum Rx. Optum Health has been a significant growth engine, with sales increasing at an average rate of 25% since 2021 and contributing $105.4 billion in revenue (19% of total sales) and a substantial 24% of total EBITDA in 2024, reflecting higher margins. However, Optum Rx, a major pharmacy benefit manager (PBM) generating $133.2 billion in revenue (24% of total) and $6.8 billion in EBITDA (18% of total) in 2024, faces considerable headwinds from potential legislative actions aimed at curtailing PBM services. The confluence of the Medicare fraud investigation and potential PBM reforms presents substantial challenges that could materially alter UnitedHealth Group's financial trajectory and operational structure, despite the strong performance of segments like Optum Health.

Key Decisions for Investors

• Investors should acknowledge the significant headwinds facing UnitedHealth Group, including the criminal investigation into its Medicare & Retirement segment and potential PBM regulatory reforms, which contribute to the stock's recent underperformance and strongly negative sentiment.
• It is critical to closely monitor developments related to the Medicare fraud investigation and any legislative actions targeting PBMs, as outcomes in these areas could materially impact substantial revenue and EBITDA contributions from key segments.
• While Optum Health demonstrates robust growth and higher margins, its positive contribution must be weighed against the considerable risks and uncertainties affecting the larger UnitedHealthcare and Optum Rx segments.
• Given the stock's significant decline, the high market impact score, and the uncertain resolution of ongoing investigations and regulatory pressures, investors should carefully re-evaluate their risk exposure to UNH and consider the potential for continued volatility.